Danaher Rides on Strength in Biotechnology Segment: Will It Sustain?

Danaher Corporation’s DHR Biotechnology segment continues to be a key contributor to its growth. In the second quarter of 2026, the segment’s reported sales rose 4% year over year to $1.92 billion. Also, its core revenues increased 2.5% on a year-over-year basis. The robust performance was led by an increase in demand for products in China.

The segment’s bioprocessing business benefited from stronger consumables demand and higher equipment sales. In the second quarter, this resulted in low-single-digit core sales growth in the bioprocessing business. The discovery and medical business also improved, supported by higher consumables sales and a better academic and research funding environment.

However, difficult prior-year comparisons weighed on the performance of this segment’s results in Western Europe and North America. Also, shipment timing shifts by large customers remain near-term concerns for the segment. These factors may continue to create some volatility in the segment’s growth trajectory.

Despite these headwinds, Danaher expects the Biotechnology segment’s core revenues to grow in the mid-single digits year over year in 2026. Healthy demand trends in the bioprocessing business, along with improving conditions in discovery and medical markets, are expected to support the Biotechnology segment’s performance in the coming quarters.

Segment Snapshot of DHR's Peers

Among its major peers, Labcorp Holdings Inc.’s LH Biopharma Laboratory Services segment generated net sales of $836.2 million in the second quarter of 2026, up 6.8% year over year. This was driven by Labcorp’s position across clinical development and ongoing demand within Central Laboratories. Labcorp derived 22.5% of its total revenues from this segment during the quarter.

Another peer of DHR, CVS Health Corporation’s CVS Health Services segment reported net sales of $51.8 billion in the second quarter of 2026, up 11.5% year over year. CVS Health generated 48.8% of its total sales from this segment in the quarter. Favorable pharmacy drug mix and brand inflation aided the segment’s results in the second quarter.

DHR's Price Performance, Valuation and Estimates

Shares of Danaher have gained 24.4% in the past month compared with the industry’s growth of 17.2%.

Image Source: Zacks Investment Research

From a valuation standpoint, DHR is trading at a forward price-to-earnings ratio of 23.90X, above the industry’s average of 16.63X.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for DHR’s 2026 earnings has increased 1.1% over the past 60 days.

Image Source: Zacks Investment Research

The company currently carries a Zacks Rank #3 (Hold).

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Radical New Technology Could Hand Investors Huge Gains

Quantum Computing is the next technological revolution, and it could be even more advanced than AI.

While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.

Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power.

Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research